Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease
Nov. 4, 2024
Werewolf Therapeutics Inc. has expanded its pipeline with the addition of a novel IL-10 Indukine development candidate, WTX-921, for inflammatory bowel disease (IBD) and potentially other inflammatory diseases.